Advertisement · 728 × 90

Posts by Dominique Guerrot

Radiology imaging of pediatric ADPKD-IFT140 cases. (A, B) Case IFT1-IV-2: MRI at 17 years of age showing 12 cysts on the right kidney and 16 on the left. The largest measures 26 mm on the lower pole of the right and 4 cm on the upper pole of the left. The majority are <5 mm in length. A: Coronal T2 image (MRI) with the arrow pointing to the 4 cm cyst with internal septation located at the upper pole of the left kidney. B: Coronal T2 MRI with the arrow pointing at the 26 mm simple cyst on the lower pole of the right kidney. (C, D) Case IFT1-IV-4: Ultrasound imaging at 4 years of age showing 3 cysts on the right kidney and none on the left. All cysts measured 2-5 mm. Longitudinal ultrasound pictures of the right kidney with the arrow pointing at the cysts. (E, F) Case IFT2-III-5: Ultrasound imaging at 9 months old showing multiple cysts on the right kidney with a 3 cm cyst on the upper pole and a 0.7 cm cyst on the left kidney.

Radiology imaging of pediatric ADPKD-IFT140 cases. (A, B) Case IFT1-IV-2: MRI at 17 years of age showing 12 cysts on the right kidney and 16 on the left. The largest measures 26 mm on the lower pole of the right and 4 cm on the upper pole of the left. The majority are <5 mm in length. A: Coronal T2 image (MRI) with the arrow pointing to the 4 cm cyst with internal septation located at the upper pole of the left kidney. B: Coronal T2 MRI with the arrow pointing at the 26 mm simple cyst on the lower pole of the right kidney. (C, D) Case IFT1-IV-4: Ultrasound imaging at 4 years of age showing 3 cysts on the right kidney and none on the left. All cysts measured 2-5 mm. Longitudinal ultrasound pictures of the right kidney with the arrow pointing at the cysts. (E, F) Case IFT2-III-5: Ultrasound imaging at 9 months old showing multiple cysts on the right kidney with a 3 cm cyst on the upper pole and a 0.7 cm cyst on the left kidney.

Monoallelic IFT140 Variants Causing Childhood-Onset Autosomal Dominant Polycystic Kidney Disease

bit.ly/3J9ZIWT

6 days ago 2 2 0 0

No thanks. See you in a few years, hopefully

1 week ago 1 0 0 0
Post image

EDITORIAL: Guidance on Care for Autosomal Dominant Polycystic Kidney Disease: A Patient Perspective

bit.ly/4bIyDEt (FREE)

3 weeks ago 4 1 0 0
Post image

Le #CJN en mode running c'est le #NEPHRORUN 🦵 l'occasion de visiter #STRASBOURG en brûlant des calories🥨 @dguerrot.bsky.social @mickaelbob.bsky.social @lobbedezt.bsky.social

1 month ago 4 3 0 0
Preview
Fanny Ruz-Guindos on X: "Villa avec piscine, notes astronomiques de champagne et de taxis … Avec @JouanAnne1 nous avons mis la palme sur un document confidentiel de l’Inspection générale des finances étrille l’Ordre des médecins. https://t.co/gtv7FT1ZWp" / X Villa avec piscine, notes astronomiques de champagne et de taxis … Avec @JouanAnne1 nous avons mis la palme sur un document confidentiel de l’Inspection générale des finances étrille l’Ordre des médecins. https://t.co/gtv7FT1ZWp

J'ai lu le rapport provisoire de l'inspection générale des finances sur l'Ordre des médecins. Accrochez-vous, c'est du brutal !
1/13

x.com/FannyRga/sta...

1 month ago 60 38 4 3
Berlin, March 16, 2026 – The Phase III study FIND-CKD, evaluating the efficacy and safety of finerenone (Kerendia™) versus placebo when added to standard of care in adult patients with non-diabetic chronic kidney disease (CKD), has met its primary endpoint. The results showed that finerenone reduced kidney function decline by achieving a statistically significant and clinically meaningful improvement versus placebo in addition to standard of care in the estimated glomerular filtration rate (eGFR) slope, defined as the mean annual rate of change in eGFR from baseline to Month 32. The eGFR slope is a validated surrogate endpoint for clinical kidney outcomes and is used as a predictive metric for the risk of kidney failure. Finerenone was well-tolerated in the FIND-CKD study, which is consistent with the well-established safety profile of finerenone. The clinical data from FIND-CKD will be presented at an upcoming scientific conference, and Bayer plans to submit the data to health authorities to extend the indication of Kerendia™ to this patient population.

Berlin, March 16, 2026 – The Phase III study FIND-CKD, evaluating the efficacy and safety of finerenone (Kerendia™) versus placebo when added to standard of care in adult patients with non-diabetic chronic kidney disease (CKD), has met its primary endpoint. The results showed that finerenone reduced kidney function decline by achieving a statistically significant and clinically meaningful improvement versus placebo in addition to standard of care in the estimated glomerular filtration rate (eGFR) slope, defined as the mean annual rate of change in eGFR from baseline to Month 32. The eGFR slope is a validated surrogate endpoint for clinical kidney outcomes and is used as a predictive metric for the risk of kidney failure. Finerenone was well-tolerated in the FIND-CKD study, which is consistent with the well-established safety profile of finerenone. The clinical data from FIND-CKD will be presented at an upcoming scientific conference, and Bayer plans to submit the data to health authorities to extend the indication of Kerendia™ to this patient population.

FIND CKD meets primary outcome (GFR slope) in n ~ 1500 with proteinuric non-diabetic CKD

Bayer press release:
www.bayer.com/media/en-us/...

BL data + design paper pubmed.ncbi.nlm.nih.gov/38858818/ in NDT

H/T Brendon Neuen on LinkedIn (!)

1 month ago 11 5 1 0
Post image

Urinary dipstick findings and UTI risk with SGLT2 inhibitors: a post hoc analysis of the CANVAS and CREDENCE trials

doi.org/10.1093/ndt/...

1 month ago 2 2 0 0
Advertisement

Thanks for sharing Joel

1 month ago 0 0 0 0
Preview
Saline Doesn’t Ruin Hyponatremia Labs (It Might Help) A study by Dr. Chienwichai highlights challenges in diagnosing hyponatremia due to undisclosed intravenous saline administration. While saline infusion does not obscure urine biochemical tests, it …

Saline Doesn’t Ruin Hyponatremia Labs (and it might help)

How many times have you been evaluating a patient in the ED and bemoaned the sneaky liter of saline they got before anyone sent some urine for analysis. Turns out it doesn't ruin the labs at all.

pbfluids.com/2026/03/sali...

1 month ago 10 7 1 0
Post image

Great to see the fantastic nephrology podcast community highlighted by #NephMadness 👍

French-speaking listeners may also enjoy #NephrOdio, a nephrology education podcast with 630K downloads to date !

1 month ago 5 4 0 0
Preview
#NephMadness 2026: The PodCrawl Submit your picks! |  @NephMadness |@nephmadness.bsky.social | NephMadness 2026 Do you prefer your information in audio form?  If so, bookmark this page, where we’ll be sharing links to NephM…

#NephMadness 2026: The PodCrawl

Featuring these podcasts:
- GN in Ten @isgd.bsky.social
- Global Kidney Care @theisn.org
- @freelyfiltered.bsky.social
- @febrilepodcast.com
- Kidney Commute @nkf-professionals.bsky.social
- @coreimpodcast.bsky.social
- Nephron Segment

bit.ly/NM26Podcrawl

1 month ago 10 10 9 0
Post image

Great to see the fantastic nephrology podcast community highlighted by #NephMadness 👍

French-speaking listeners may also enjoy #NephrOdio, a nephrology education podcast with 630K downloads to date !

1 month ago 5 4 0 0

Pouvez-vous donner le lien vers l’étude citée svp ? Merci

1 month ago 1 0 1 0
A visual representation of the FINE-ONE trial, which assessed the efficacy and safety of finerenone among patients with CKD and type 1 diabetes.

A visual representation of the FINE-ONE trial, which assessed the efficacy and safety of finerenone among patients with CKD and type 1 diabetes.

Finerenone improves kidney and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes, but its efficacy in type 1 diabetes is unknown. The FINE-ONE trial involving patients with CKD and type 1 diabetes is summarized in a new Quick Take video. nej.md/3PcIJWt

1 month ago 5 3 0 0
Advertisement

And ADPKD excluded… pending results of DAPA-PKD & STOP-PKD

1 month ago 3 0 0 0
Post image

This prospective study in #ASNJASN of 976 adults measured the association between subclinical primary aldosteronism and kidney outcomes. Read more: kidney.pub/JASN1039 Rémi Goupil



1 month ago 5 2 0 0
Preview
ERKNet Survey | Blood Pressure Management in ADPKD - A European Survey of Clinical Practice Take this survey powered by surveymonkey.com. Create your own surveys for free.

🙋‍♀️🙋‍♂️ Help shape practice on hypertension in ADPKD!

🔎 An ERKNet survey for adult & pediatric nephrologists, based on a PKD France initiative with support by ERA Kidney & Genes WG and ESPN 🇪🇺

Many thanks for your input !

Dominique Guerrot & Djalila Mekahli

2 months ago 3 7 0 0

Le papier est étrange pour un néphrologue. Il répond à une question qu’on ne se posait pas vraiment… et le résultat n’est pas très surprenant, ça tombe bien 😅

2 months ago 1 0 0 0
Preview
ERKNet Survey | Blood Pressure Management in ADPKD - A European Survey of Clinical Practice Take this survey powered by surveymonkey.com. Create your own surveys for free.

🙋‍♀️🙋‍♂️ Help shape practice on hypertension in ADPKD!

🔎 An ERKNet survey for adult & pediatric nephrologists, based on a PKD France initiative with support by ERA Kidney & Genes WG and ESPN 🇪🇺

Many thanks for your input !

Dominique Guerrot & Djalila Mekahli

2 months ago 3 7 0 0
Preview
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198 In focal segmental glomerulosclerosis (FSGS), transient receptor potential cation channel, subfamily C, member 6 (TRPC6) overactivity might cause podo…

www.sciencedirect.com/science/arti...

Podocyte targeted therapy:
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198

2 months ago 3 1 0 0
Preview
Protein Intake and Mortality in Older Adults With CKD This multicohort study estimates the associations of total, animal, and plant protein intake with all-cause mortality in older adults with mild or moderate chronic kidney disease (CKD) and compares th...

Protein Intake and Mortality in Older Adults With CKD url: jamanetwork.com/journals/jam... discovered thanks to @cyrilmousseaux.bsky.social

2 months ago 2 1 1 0
Advertisement
Four graphs display events prevented or caused per 1000 patients treated with a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor for 1 Year by Diabetes Status and Level of Albuminuria. The graphs show variance for diabetes vs. no diabetes.

Four graphs display events prevented or caused per 1000 patients treated with a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor for 1 Year by Diabetes Status and Level of Albuminuria. The graphs show variance for diabetes vs. no diabetes.

Meta-analysis: #SGLT2 inhibitors slow kidney decline consistently across CKD severity and albuminuria range, supporting their routine use for kidney health.

ja.ma/4pNzTve

3 months ago 5 2 1 0
Post image

CKD prevalence in elderly and the eGFR inflation effect, a very important paper in the @ndt-era.bsky.social . Not just for elderly but also for the young CKD population

academic.oup.com/ndt/article/...

#nephinp
#nephrology_in_practice

4 months ago 5 3 0 0
Splash slide

Splash slide

#NephGR tomorrow at @ottawahospital.on.ca

Tristan De Nattes from Rouen on treating ABMR

#NephSky

4 months ago 6 2 0 0
Preview
Découverte de valves au cœur du système lymphatique cardiaque et de leur rôle dans l’insuffisance cardiaque - Salle de presse de l'Inserm Dans une nouvelle étude, des chercheurs de l’Inserm et de l’Université de Rouen Normandie, en collaboration avec une équipe de l’Université de Wurtzbourg (Allemagne), ont analysé comment le système ly...

Dans une nouvelle étude des scientifiques de l'Inserm ont analysé comment le système lymphatique se dérègle dans l’insuffisance cardiaque. Ils ont, pour la première fois, identifié les mécanismes responsables de ce dysfonctionnement.

Lire le communiqué : presse.inserm.fr/decouverte-d...

4 months ago 15 6 1 0
Infographic from JAMA. Question: Does sodium bicarbonate decrease mortality at 90 days for patients with acidosis & acute kidney injury? Conclusion: No improvement. Findings: Sodium bicarbonate 62.1%, Control 61.7%.

Infographic from JAMA. Question: Does sodium bicarbonate decrease mortality at 90 days for patients with acidosis & acute kidney injury? Conclusion: No improvement. Findings: Sodium bicarbonate 62.1%, Control 61.7%.

For critically ill patients who had both severe metabolic acidemia and moderate to severe acute kidney injury, sodium bicarbonate therapy did not significantly decrease day 90 all-cause mortality.

ja.ma/4pFsAWU

4 months ago 6 3 1 2

Well actually you wrote “renal” instead of “kidney” in a Twitter post in 2022… Access denied, sorry

4 months ago 2 0 0 0
Preview
Hypertension, un danger silencieux : venez participer à notre matinée de sensibilisation jeudi Hypertension, un danger silencieux : venez participer à notre matinée de sensibilisation jeudi

Hypertension, un danger silencieux : venez participer à une matinée de sensibilisation jeudi 11 décembre à Marseille. www.laprovence.com/article/sant... #santé #hypertension

4 months ago 4 1 1 0
Preview
Renal PIEZO2 is an essential regulator of renin The force-sensing ion channel PIEZO2 is an essential regulator of the renin-angiotensin-aldosterone system (RAAS), a pathway that controls blood volume. Loss of PIEZO2 in the kidney cells that produce...

A long delay between pre print and publication means this paper only got better and better. Congrats @rose-hill.bsky.social and all collaborators, including many in renal physiology. A role for PIEZO2 in sensing pressure in the kidney and regulating the renin pathway. www.cell.com/cell/fulltex...

4 months ago 53 6 3 0
Post image

Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study

bit.ly/3ZdrYxb #OpenAccess

#VisualAbstract #CKD

4 months ago 3 1 0 0
Advertisement